-
Chromatin remodellers as therapeutic targets Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-16 Hayden A. Malone, Charles W. M. Roberts
-
Data science in pharmaceutical R&D: the DISRUPT-DS industry roundtable Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-15 Najat S. Khan, Thomas Senderovitz, James Weatherall, Janice Branson, Benedikt Egersdoerfer, Eric Genevois-Marlin, Sai Jasti, Mustaqhusain Kazi, Ranjit Kumble, Patrick Loerch, Justine Rochon, Venkat Sethuraman, Matt Studney, Xiaoying Wu, Ryan Copping, Priya Chandran, Dhruv Jayanth, Christoph Meier
The DISRUPT-DS roundtable, which brings together data science leaders from large pharmaceutical companies, aims to be a forum for sharing experiences and networking, for shaping industry-level topics and for amplifying the role of data science across pharmaceutical R&D.
-
FDA new drug approvals in Q2 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-15
Discover the world’s best science and medicine | Nature.com
-
A rush of CRISPR to the lungs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-10
Discover the world’s best science and medicine | Nature.com
-
Targeting ROS in cancer: rationale and strategies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-09 Christophe Glorieux, Shihua Liu, Dunyaporn Trachootham, Peng Huang
-
FDA approves third anti-amyloid antibody for Alzheimer disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-05
Discover the world’s best science and medicine | Nature.com
-
Rebalancing calcium in Alzheimer disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-05
Discover the world’s best science and medicine | Nature.com
-
The 60-year evolution of lipid nanoparticles for nucleic acid delivery Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-04 P. R. Cullis, P. L. Felgner
-
Enhancing in situ cancer vaccines using delivery technologies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-07-01 Ningqiang Gong, Mohamad-Gabriel Alameh, Rakan El-Mayta, Lulu Xue, Drew Weissman, Michael J. Mitchell
-
When chronic and rare disease worlds converge Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Sharon Barr, head of BioPharmaceuticals R&D at AstraZeneca, discusses her chronic disease research priorities, including the need for new diagnostic tools, fixed-dose drugs and a better understanding of disease biology.
-
Machine learning identifies AMPs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
Discovering CFTR modulators Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
ETS2 drives IBD Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
A selective microbiome-sparing antibiotic Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-27
Discover the world’s best science and medicine | Nature.com
-
Gene therapies start the climb from rare disease base camps to common disease peaks Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-25
Jude Samulski, former CSO and co-founder of AskBio, discusses the future of gene therapy for complex and common diseases, including Parkinson disease and congestive heart failure.
-
FDA approves 21-valent pneumococcal vaccine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-21
Discover the world’s best science and medicine | Nature.com
-
Menin inhibitors seek to debut as newest targeted therapy for leukaemia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-21
Small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias.
-
CAR T cells take to the airways Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-19
Discover the world’s best science and medicine | Nature.com
-
Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-18 Terry Kenakin
-
Extracellular targeted protein degrader removes antibodies in first test in humans Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-18
Biohaven’s BHV-1300 lowered levels of immunoglobulin G in the blood of healthy volunteers — a first clinical demonstration of the potential of a small-molecule extracellular protein degrader.
-
FDA approves first telomerase inhibitor Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-14
Discover the world’s best science and medicine | Nature.com
-
Upcoming market catalysts in Q3 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-12
Discover the world’s best science and medicine | Nature.com
-
Chromatin-targeted drug discovery at “a very special moment” Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-11
Cigall Kadoch, a cancer researcher at Dana-Farber Cancer Institute and co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs, targeting chromatin remodelling complexes.
-
Antisense and CRISPR-based drugs build cases for better hereditary angioedema treatments Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-11
Discover the world’s best science and medicine | Nature.com
-
Expanding the psychedelic toolkit Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-10
Discover the world’s best science and medicine | Nature.com
-
RNA delivery heats up cold tumours Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-10
Discover the world’s best science and medicine | Nature.com
-
A route to small-molecule Lp(a) inhibitors for heart disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-10
Discover the world’s best science and medicine | Nature.com
-
FDA approves mRNA-based RSV vaccine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-07
Discover the world’s best science and medicine | Nature.com
-
Sequential immunotherapy: towards cures for autoimmunity Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-06-05 Francisco Ramírez-Valle, Joseph C. Maranville, Sophie Roy, Robert M. Plenge
-
Reducing seizures with senolytic drugs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-31
Discover the world’s best science and medicine | Nature.com
-
Assessing accuracy of AlphaFold2 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-31
Discover the world’s best science and medicine | Nature.com
-
Predicting ligand–protein interactions Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-31
Discover the world’s best science and medicine | Nature.com
-
Designing reversible anticoagulants Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-31
Discover the world’s best science and medicine | Nature.com
-
The changing landscape of cancer cell therapies: clinical trials and real-world data Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-31
Discover the world’s best science and medicine | Nature.com
-
Dual-acting GLP-1 conjugate enhances weight loss Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-29
Discover the world’s best science and medicine | Nature.com
-
Drug discovery for ageing: SIMPs, NEDs and screening challenges Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-29 Richard G. A. Faragher, Richard C. Hartley
Drugs that modulate fundamental mechanisms of ageing offer the promise of substantially improving the health of ageing populations, but innovative approaches to identify and evaluate such ‘gerotherapeutics’ are needed.
-
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-24
Discover the world’s best science and medicine | Nature.com
-
Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-23 Giacomo Capone, Björn Eriksson, Monique Al, Stan van Belkum, Karl Broich, Maria Lamas, Marianne Lunzer, Lorraine Nolan, Catriona Ester, Juan Garcia Burgos, Laura Pioppo, Ana Zanoletty, Peter Arlett
Accelerating Clinical Trials in the EU (ACT EU) is an initiative developed by the European Commission, Heads of Medicines Agencies and the European Medicines Agency to transform the clinical trials landscape in the European Union. It aims to foster regulatory, technological and process innovation to support better, faster and optimized clinical trials.
-
Navigating the complexities of drug development for inflammatory bowel disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-22 Sailish Honap, Vipul Jairath, Silvio Danese, Laurent Peyrin-Biroulet
-
The state of the art in secondary pharmacology and its impact on the safety of new medicines Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-21 Richard J. Brennan, Stephen Jenkinson, Andrew Brown, Annie Delaunois, Bérengère Dumotier, Malar Pannirselvam, Mohan Rao, Lyn Rosenbrier Ribeiro, Friedemann Schmidt, Alicia Sibony, Yoav Timsit, Vicencia Toledo Sales, Duncan Armstrong, Armando Lagrutta, Scott W. Mittlestadt, Russell Naven, Ravikumar Peri, Sonia Roberts, James M. Vergis, Jean-Pierre Valentin
-
RNA-rewriting candidate moves into the clinic Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-20
‘Pre-mRNA trans-splicing’ drugs could offer an alternative to gene replacement therapies for genetic diseases — starting with Stargardt disease.
-
Publisher Correction: Roflumilast Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-15 Leonardo M. Fabbri, Bianca Beghé, Uma Yasothan, Peter Kirkpatrick
-
Combating antimicrobial resistance in malaria, HIV and tuberculosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-15 Maëlle Duffey, Robert W. Shafer, Juliano Timm, Jeremy N. Burrows, Nader Fotouhi, Mark Cockett, Didier Leroy
-
Tackling the challenges of new approach methods for predicting drug effects from model systems Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-15 Paul D. Pang, Syed Mukhtar Ahmed, Masataka Nishiga, Norman L. Stockbridge, Joseph C. Wu
The passage of the FDA Modernization Act 2.0 in 2022 has provided additional impetus to develop new approach methods for predicting the effects of drug candidates in humans from models such as microphysiological systems based on human-derived induced pluripotent stem cells. Here, we highlight progress in the field and strategies to address various challenges, including the application of artificial
-
CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-13
Discover the world’s best science and medicine | Nature.com
-
Bispecific antibody takes a BiTE out of B cells in rheumatoid arthritis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-13
Discover the world’s best science and medicine | Nature.com
-
Frameworks for transformational breakthroughs in RNA-based medicines Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-13 John R. Androsavich
-
New route to target RAS Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-10
Discover the world’s best science and medicine | Nature.com
-
WRN inhibitors squeeze cancer cell vulnerability Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-08
Discover the world’s best science and medicine | Nature.com
-
Development of Chinese innovative drugs in the USA Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-08
Discover the world’s best science and medicine | Nature.com
-
First, do no harm: a global perspective on diversity and inclusion in clinical trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-08 Katharine Wright, Willyanne DeCormier Plosky, Hayat R. Ahmed, Sarah A. White, Barbara E. Bierer
New requirements for clinical trial sponsors to submit diversity action plans to the US Food and Drug Administration (FDA) are an important step to embed planning for diverse representation in clinical trial research. These must not, however, be implemented in ways that are detrimental to other countries’ health and research interests.
-
Designing novel macrocyclic drugs Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-07
Discover the world’s best science and medicine | Nature.com
-
Targeting ephrin signalling in sepsis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-07
Discover the world’s best science and medicine | Nature.com
-
ASO to treat Timothy syndrome Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-07
Discover the world’s best science and medicine | Nature.com
-
Mapping cysteine ligandability Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-05-03
Discover the world’s best science and medicine | Nature.com
-
Efficiency, effectiveness and productivity in pharmaceutical R&D Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-04-29
Discover the world’s best science and medicine | Nature.com
-
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-04-26
Discover the world’s best science and medicine | Nature.com
-
RIPK3 inhibitor prevents lung damage in severe influenza infection Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-04-24
Discover the world’s best science and medicine | Nature.com
-
mRNA therapy shows promise for metabolic disorder Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-04-23
Discover the world’s best science and medicine | Nature.com
-
RNA-editing drugs advance into clinical trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-04-18
ADAR-based editors that can change the mRNA code offer new opportunities in both rare genetic diseases and common complex ones.